Background--The expression of a novel cardiac glucose transporter, SGLT1, is increased in glycogen storage cardiomyopathy secondary to mutations in PRKAG2. We sought to determine the role of SGLT1 in the pathogenesis of PRKAG2 cardiomyopathy and its role in cardiac structure and function.
Background--The expression of a novel cardiac glucose transporter, SGLT1, is increased in glycogen storage cardiomyopathy secondary to mutations in PRKAG2. We sought to determine the role of SGLT1 in the pathogenesis of PRKAG2 cardiomyopathy and its role in cardiac structure and function.
Methods and Results--Transgenic mice with cardiomyocyte-specific overexpression of human T400N mutant PRKAG2 cDNA (TG T400N ) and transgenic mice with cardiomyocyte-specific RNA interference knockdown of SGLT1 (TG SGLT1-DOWN ) were crossed to produce double-transgenic mice (TG T400N /TG
SGLT1-DOWN
). Tet-off transgenic mice conditionally overexpressing cardiac SGLT1 in the absence of doxycycline were also constructed (TG SGLT-ON ). Relative to TG T400N mice, TG T400N /TG SGLT1-DOWN mice exhibited decreases in cardiac SGLT1 expression (63% decrease, P<0.05), heart/body weight ratio, markers of cardiac hypertrophy, and cardiac glycogen content. TG T400N /TG SGLT1-DOWN mice had less left ventricular dilation at age 12 weeks compared to TG T400N mice. Relative to wildtype (WT) mice, TG SGLT1-ON mice exhibited increases in heart/body weight ratio, glycogen content, and markers of cardiac hypertrophy at ages 10 and 20 weeks. TG SGLT1-ON mice had increased myocyte size and interstitial fibrosis, and progressive left ventricular dysfunction. When SGLT1 was suppressed after 10 weeks of overexpression (TG SGLT1-ON/OFF ), there was a reduction in cardiac hypertrophy and improvement in left ventricular failure.
Conclusions--Cardiac knockdown of SGLT1 in a murine model of PRKAG2 cardiomyopathy attenuates the disease phenotype, implicating SGLT1 in the pathogenesis. Overexpression of SGLT1 causes pathologic cardiac hypertrophy and left ventricular failure that is reversible. This is the first report of cardiomyocyte-specific transgenic knockdown of a target gene. ( J Am Heart Assoc. 2014;3:e000899 doi: 10.1161/JAHA.114.000899) Key Words: cardiomyopathy • glucose • heart failure • hypertrophy A MP-activated protein kinase (AMPK), a heterotrimeric protein composed of a catalytic a subunit and regulatory b and c subunits, is activated under conditions of energy depletion manifested by increased cellular AMP levels. 1, 2 Mutations in the gene PRKAG2, encoding the cardiac c2 regulatory subunit of AMPK, have been demonstrated to produce a distinct glycogen storage cardiomyopathy in human families. 3 We and others have shown that inappropriate activation of AMPK by PRKAG2 mutations [4] [5] [6] [7] leads to increased cardiac glucose uptake and glycogen synthesis 8 and activation of cardiac hypertrophic signaling pathways. 9, 10 Classically, it has been thought that only the GLUT isoforms GLUT1 and GLUT4 are responsible for glucose uptake in cardiomyocytes. 11 However, we have recently reported that the sodium-dependent glucose co-transporter (SGLT) isoform SGLT1 is present at the protein level in cardiomyocytes, and appears to be localized to the sarcolemma. 12 SGLTs transport glucose by a secondary active transport mechanism that uses the sodium concentration gradient established by the Na + /K + -ATPase pump. We recently showed that cardiac SGLT1 expression is increased in PRKAG2 cardiomyopathy, and that the increased cardiac glucose uptake appears to be mediated partly by SGLT1. 13 Specifically, the pharmacological SGLT1 inhibitor phlorizin reduces glycogen storage in PRKAG2 cardiomyopathy. However, whether long-term specific inhibition of SGLT1 in cardiomyocytes by genetic means results in a reduction in cardiac hypertrophy or improvement in cardiac function is unknown. Furthermore, the effect of overexpression of SGLT1 on the heart is also unknown. Therefore, the objective of the present study was to investigate whether transgenic knockdown of cardiac SGLT1 (TG SGLT1-DOWN ) in mice with the PRKAG2 Thr400Asn mutation (TG  T400N ) to negative control scrambled siRNA ( Figure 1 ). We used the sequence of siRNA no. MSS277112 (Invitrogen), which resulted in the greatest RNA interference and reduction of protein levels of SGLT1 in isolated cells, to construct a transgenic mouse model (TG SGLT1-DOWN ) expressing short hairpin RNA for RNA interference of SGLT1. The transgene construct places the short hairpin RNA within a pC126 expression vector (a generous gift of Dr Jeffrey Robbins, University of Cincinnati), containing a highly active cardiomyocyte-specific a-myosin heavy-chain promoter. 4, 15, 16 Prior to insertion into this vector, the siRNA was cloned into a segment of murine genomic DNA comprising the first 1000 bp of the third intron of the murine a-myosin heavychain gene, at a Bam HI site at a position 595 bp 3 0 to the start of the intronic segment. This construct was linearized, size-fractionated, purified, and micro-injected into fertilized FVB mouse oocytes at the University of Pittsburgh Transgenic and Chimeric Mouse Facility. The construction of the transgenic mouse with the human T400N mutation in PRKAG2 (TG T400N ) has been previously described. 4 
Construction of the SGLT1 Conditionally Overexpressing (TG SGLT1-ON ) Mouse
Constitutive cardiac transgenic overexpression of SGLT1 was lethal at the embryonic or early neonatal stages (data not shown). Therefore, to be able to regulate cardiac transgene expression, a tetracycline-suppressible binary a-MHC-driven system was used. 17 The transactivator protein, tTA, is required for robust expression of the target responder under the inhibitory control of doxycycline.
Genotyping
Tail snips were collected, DNA was extracted, and genotyping was performed by multiplex polymerase chain reaction with primers specific for each transgene (Table 1) . Internal controls included primers for essential myosin light chain and control mouse genomic DNA.
Study Protocol for the Conditional Overexpression of SGLT1
The expression of SGLT1 was suppressed in all transgenic mice during conception to age 4 weeks postnatally by administering doxycycline-containing food (625 mg/kg; Harlan Laboratories) to pregnant and nursing mothers and to weaned offspring.
To study the effects of SGLT1 overexpression on cardiac pathology and function, TG SGLT1 male and female mice >4 weeks of age were placed in 2 experimental groups, SGLT1 suppression (TG SGLT1-OFF ) and SGLT1 overexpression (TG SGLT1-ON ), and analyzed at either 10 or 20 weeks of age. In addition, to study the reversibility of the effects of cardiac SGLT1 overexpression, mice were exposed to SGLT1 overexpression at 4 to 10 weeks of age, followed by SGLT1 suppression at 10 to 20 weeks of age (TG SGLT1-ON/OFF ) ( Figure 2 ).
RNA Analyses
Total RNA was isolated from whole hearts and real-time quantitative polymerase chain reaction analysis performed as 
described. 16 Primers for quantitative polymerase chain reaction analysis were designed using published sequence information, avoiding regions of homology with other genes (Table 2) . Fold-changes were calculated with normalization to cyclophilin transcript levels.
Protein Analyses
Extraction of total cardiac protein was performed as described previously. 9 The extraction of membrane proteins from cardiac tissue was performed using a commercially available kit (no. k268-50; BioVision) according to the manufacturer's instructions. For membrane protein extraction, 5 to 8 pooled hearts of each genotype totaling at least 1 g in mass were homogenized and processed. The a1 subunit of the Na + /K + -ATPase, a sarcolemmal membrane marker, was quantified by immunoblot to document adequate enrichment and equal loading of membrane proteins. Immunoblots were performed with antibodies specific for SGLT1 (sc-20582; Santa Cruz), GLUT1 (ab40084; Abcam), GLUT4 (2213s; Cell Signaling), Na + /K + ATPase (3010s; Cell Signaling), AMPKa (2532; Cell Signaling), phospho-Thr 172 AMPKa (2531; Cell Signaling), and GAPDH (ab8245; Abcam).
Analysis of Glycogen Content
Glycogen content was determined by the amyloglucosidase digestion method.
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Histopathology
Sections were stained with hematoxylin and eosin to assess myofiber architecture, Masson's trichrome to assess interstitial fibrosis, and periodic acid-Schiff to assess glycogen content.
5
For quantitative histomorphometry, hematoxylin and eosinstained samples were used. Five separate regions per slide were photographed at 409 with myocytes predominantly oriented in cross section. Micrographs were digitized and nucleated myofibers were traced using Image J 1.44p software (National Institutes of Health, Bethesda, MD) in a blinded fashion. Twenty-five myofibers per heart were examined. 19 
Echocardiography
Transthoracic echocardiography was performed on mice after sedation with tribromoethanol (125 mg/kg IP) using a VisualSonics Vevo 770 machine with a 45-MHz transducer. 18 Left ventricular end diastolic (LVEDD) and end systolic (LVESD) chamber dimensions and anterior wall thickness (LVAWT) were obtained from M-mode tracings. LV fractional shortening was calculated as (LVEDDÀLVESD)/LVEDD9100%.
Statistical Analysis
Data are expressed as the meanAESE. Statistical analysis was performed using the R program 3. DOWN ) . A, The sequence of siRNA no. MSS277112 (Invitrogen), which resulted in the greatest RNA interference and reduction of protein levels of SGLT1 in isolated cells (Figure 1) , was used to construct a transgenic mouse model (TG SGLT1-DOWN ) expressing hairpin shRNA for RNA interference of SGLT1. The transgene construct places the shRNA within a pC126 expression vector, containing a highly active cardiomyocyte-specific aMHC promoter. Prior to insertion into this vector, the siRNA was cloned into a segment of murine genomic DNA comprising the first 1000 bp of the third intron of the murine aMHC gene, at a Bam HI site at a position 595 bp 3 0 to the start of the intronic segment. B, Relative total cardiac SGLT1 mRNA expression and (C) membrane SGLT1 protein expression in WT, TG age ( Figure 4D ). There was no significant qualitative difference in the levels of membrane-associated GLUT4 between TG SGLT1-DOWN and WT mice, although there appeared to be a reduction in membrane-associated GLUT1 protein ( Figure 5 ). There were no morphologic abnormalities in myocyte architecture evident in TG SGLT1-DOWN hearts stained with hematoxylin and eosin ( Figure 4E ). Finally, TG SGLT1-DOWN hearts exhibited no differences in AMPK activity relative to WT mice, as reflected by expression of phospho-Thr 172 AMPKa (Figure 6 ).
SGLT1 Knockdown Attenuates Glycogen Storage, Cardiac Hypertrophy, and LV Dysfunction in PRKAG2 Cardiomyopathy
We have previously reported that pharmacological inhibition of SGLT1 by the competitive inhibitor phlorizin decreased cardiac glycogen content and inhibited cardiac glucose uptake in TG T400N mice. 13 However, phlorizin is not completely selective for SGLT1, and has systemic effects in noncardiac tissue. In order to ascertain the role of SGLT1 in PRKAG2 cardiomyopathy, we generated TG T400N /TG SGLT1-DOWN mice.
Relative to TG T400N mice, TG T400N /TG SGLT1-DOWN mice exhibited significant reductions in heart-to-body-weight ratio, and in Nppa and Nppb transcript levels ( Figure 4A through 4C) . The significant 23% reduction in cardiac glycogen content in TG T400N /TG SGLT1-DOWN mice relative to TG T400N mice was similar to our previous finding using phlorizin ( Figure 4D ). Histological examination with hematoxylin and eosin confirmed a decrease in glycogen-laden myocytes in TG T400N / TG SGLT1-DOWN mice relative to TG T400N mice ( Figure 4E ).
In addition, TG T400N /TG SGLT1-DOWN mice at 7 weeks of age had increased fractional shortening relative to all other groups of mice ( Figure 5 ).
Conditional Cardiac Overexpression of SGLT1 Leads to Cardiac Glycogen Accumulation, Hypertrophy, Fibrosis, and Contractile Dysfunction
The conditional system showed robust control of cardiac SGLT1 expression by doxycycline. TG SGLT1-ON mice exhibited an increase in SGLT1 transcript and membrane protein levels at 10 and 20 weeks of age relative to WT and TG SGLT1-OFF mice (Figure 7 ). In addition, TG SGLT1-ON/OFF mice had a reduction in SGLT1 transcript and membrane protein expression at 20 weeks of age to levels comparable to baseline. Furthermore, TG SGLT1-ON hearts at 10 weeks of age exhibited no differences in AMPK activity relative to WT mice, as reflected by expression of phospho-Thr 172 AMPKa (Figure 6 ). At 10 weeks of age, TG SGLT1-ON mice showed significant increases in heart-to-body-weight ratio relative to WT mice ( Figure 8A ) that were associated with significant increases in the expression of the hypertrophy biomarkers Nppa and Nppb ( Figure 8B and 8C) . Furthermore, they exhibited a 16.5-fold increase in cardiac glycogen content ( Figure 8D ). On echocardiography at 10 weeks, TG SGLT1-ON mice relative to WT mice had an increase in LV end-diastolic dimension (P<0.005), and a decrease in fractional shortening (P<0.005) indicating contractile dysfunction (Table 4) . 
Effects of Cardiac SGLT1 Overexpression Are Reversible
To determine whether the effects of SGLT1 overexpression in the heart can be reversed, the SGLT1 transgene was suppressed from 10 to 20 weeks of age by the administration of doxycycline in chow (TG
SGLT1-ON/OFF
). TG SGLT1-ON/OFF mice exhibited a reduction in glycogen content compared to 10-week-old and 20-week-old TG SGLT1-ON mice (Figure 8 ). In addition, heart-to-body-weight ratios and markers of cardiac hypertrophy were decreased in TG mice exhibited a reduction in myocyte size relative to Figure 6 . Total cardiac protein immunoblots showed that levels of phospho-Thr 172 AMPKa (pAMPK), reflecting AMPK activity, were not significantly different in WT, TG SGLT1-DOWN , and TG SGLT1-ON mice at the age of 10 weeks. Densitometry plots were normalized to GAPDH signal. AMPK indicates AMP-activated protein kinase; SGLT1, sodium-dependent glucose co-transporter 1; WT, wildtype. TG SGLT1-ON mice at both 10 and 20 weeks of age ( Figure 9 ). In addition, TG SGLT1-ON/OFF mice showed a qualitative decrease in interstitial fibrosis on Masson's trichrome stain and a significant decrease in procollagen-1 transcript level compared to 20-week-old TG SGLT1-ON mice.
Discussion
Transgenic mouse models of the Thr400Asn (TG T400N ) 4 and the Asn488Ile (TG N488I ) 18 mutations in PRKAG2 recapitulate the human glycogen storage cardiomyopathy. These mice exhibit an initial inappropriate activation of AMPK. In vivo cardiac glucose uptake is elevated early in TG T400N mice, and in TG N488I hearts the increased glucose entry is directed toward glycogen synthesis. 8 The mechanism of increased cardiac glucose uptake had remained uncertain until our recent discovery that SGLT1 is upregulated in TG T400N cardiomyocytes. 13 Our data establish a role for SGLT1 in the pathophysiology of PRKAG2 cardiomyopathy. Cardiomyocyte-specific knockdown of SGLT1 by transgenic RNA interference led to a reduction in cardiac mass, cardiac glycogen content, markers of hypertrophy, histopathological abnormalities, and structural and functional abnormalities on echocardiogram. Although cardiac membrane GLUT1 protein expression was mildly decreased in TG SGLT1-DOWN relative to WT mice, no difference was observed in TG T400N /TG SGLT1-DOWN relative to TG T400N mice. Therefore, the attenuation in phenotype in TG T400N /TG SGLT1-DOWN mice was not attributable to changes in GLUT1 expression. The reduction in glycogen content with SGLT1 knockdown was modest but similar to the reduction we previously observed with chronic administration of phlorizin, a pharmacological inhibitor of SGLT1. However, despite modest changes in glycogen content and no significant change in wall thickness, we observed significant histological and functional improvements in TG T400N /TG SGLT1-DOWN relative to TG T400N mice. PRKAG2 cardiomyopathy is associated with increased fractional shortening early in the course of the disease, which is followed by worsening LV function and dilation. 4 The TG T400N /TG SGLT1-DOWN mice exhibited a delay in the progression of LV dysfunction. These mice had increased fractional shortening at 7 weeks of age and a trend towards improved fractional shortening compared to TG T400N mice at 12 weeks of age.
Although our data provide strong evidence for a role of SGTL1 in PRKAG2 cardiomyopathy, SGLT1 knockdown only partially attenuates the phenotype, and TG T400N /TG SGLT1-DOWN mice still exhibit LV hypertrophy and eventual dysfunction. It is likely that some of the excess glucose entry is mediated by other glucose transporters, such as the facilitative glucose transporters GLUT1 and GLUT4. Moreover, the reduction in SGLT1 expression is incomplete, in the range of 80%. A cardiac-specific SGLT1 knockout model may exhibit greater attenuation of the phenotype. However, the knockdown model may more closely mirror clinical practice, in the setting of drug therapy for PRKAG2 cardiomyopathy. It is also likely that the cardiac hypertrophy in PRKAG2 cardiomyopathy is not completely attributable to glycogen deposition. We and others previously showed that much of the hypertrophy may be related to activation of hypertrophic signaling pathways such as NF-jb and Akt. Figure 8 . TG SGLT1-ON mice exhibited increases relative to WT mice in heart-to-body-weight ratio (A), glycogen content (B), and markers of cardiac hypertrophy (C and D) at 10 and 20 weeks of age. There was a significant reduction in heart-to-body-weight ratio, glycogen content, and markers of hypertrophy in TG SGLT1-ON/OFF relative to TG SGLT1-ON mice at age 20 weeks. Heart-to-body-weight ratio: WT, N=4; TG Our data also suggest that the deleterious effects of SGLT1 overexpression in the heart can be reversed if the overexpression is suppressed. TG SGLT1-ON/OFF mice had decreased glycogen content and cardiomyocyte size, and improved LV function relative to TG SGLT1-ON mice at 10 weeks of age. This observation has potential clinical relevance, since the cardiac remodeling activated by SGLT1 overexpression has potential for reversal. The mechanism of increased SGLT1 expression in PRKAG2 cardiomyopathy remains to be elucidated. Inappropriate activation of AMPK is likely to be the initiating event. We have previously reported 13 that pharmacological activation of AMPK in WT hearts results in an increase of SGLT1 transcript levels (and unpublished data). Furthermore, we have found that other acquired heart disease associated with AMPK activation, such as ischemia, is associated with increased SGLT1 expression. 12 Classically, it has been thought that cardiac glucose uptake is mediated primarily by GLUT1 and GLUT4. Although SGLT1 protein has been known to be expressed in the small intestine and renal cells, 20 we have only recently determined that it is highly expressed in the heart. 12 The role that SGLT1 plays in cardiac physiology and pathophysiology is still largely unknown. Recently, it has been reported that inhibition of SGLT1 in isolated human cardiomyocytes has a negative inotropic effect. 21, 22 In addition, Balteau et al have shown that NOX2 activation in primary cultures of adult rat cardiomyocytes results from glucose transport through SGLT1. 23 Our current report is the first to describe a role of SGLT1 in cardiac disease. In this study, we demonstrate that knockdown of SGLT1 in the murine heart by the transgenic overexpression of cardiomyocyte-specific short hairpin RNA to SGLT1 is feasible. To our knowledge, this report is the first description of the successful use of this strategy, and also the first description of transgenic knockdown of cardiac SGLT1 showing benefit in an animal model of human cardiac disease.
While this study focused on the role of SGLT1 in PRKAG2 cardiomyopathy, other forms of human cardiac disease may potentially involve SGLT1. 12 With the ongoing development of new drug inhibitors for the sodium glucose co-transporter family, primarily for diabetes, there may be a potential role for these drugs in the treatment of cardiac disease.
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